Skip to main content
Journal cover image

Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies

Publication ,  Journal Article
Costa, LJ; Maddocks, K; Epperla, N; Reddy, NM; Karmali, R; Umyarova, E; Bachanova, V; Costa, C; Glenn, MJ; Chavez, JC; Calzada, O; Lansigan, F ...
Published in: American Journal of Hematology
February 2017

The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse < 6 months from end of therapy (early relapse; ER). Median age was 58 years and response to salvage was 41.7%. Two‐year OS was 18.5% in PP, 30.6% in RD and 45.5% in ER. The presence of PP, intermediate‐high/high NCCN‐IPI at time of PTF or translocation predicted 2‐year OS of 13.6% constituting ultra‐high risk (UHR) features. Among the 132 patients who underwent autologous hematopoietic cell transplantation, 2‐year OS was 74.3%, 59.6% and 10.7% for patients with 0,1 and 2–3 UHR features respectively. Patients with PTF and UHR features should be prioritized for clinical trials with newer agents and innovative cellular therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

American Journal of Hematology

DOI

EISSN

1096-8652

ISSN

0361-8609

Publication Date

February 2017

Volume

92

Issue

2

Start / End Page

161 / 170

Publisher

Wiley

Related Subject Headings

  • Immunology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Costa, L. J., Maddocks, K., Epperla, N., Reddy, N. M., Karmali, R., Umyarova, E., … Hamadani, M. (2017). Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies. American Journal of Hematology, 92(2), 161–170. https://doi.org/10.1002/ajh.24615
Costa, Luciano J., Kami Maddocks, Narendranath Epperla, Nishitha M. Reddy, Reem Karmali, Elvira Umyarova, Veronika Bachanova, et al. “Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies.” American Journal of Hematology 92, no. 2 (February 2017): 161–70. https://doi.org/10.1002/ajh.24615.
Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, et al. Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies. American Journal of Hematology. 2017 Feb;92(2):161–70.
Costa, Luciano J., et al. “Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies.” American Journal of Hematology, vol. 92, no. 2, Wiley, Feb. 2017, pp. 161–70. Crossref, doi:10.1002/ajh.24615.
Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez‐Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero‐Torres A, Al‐Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M. Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies. American Journal of Hematology. Wiley; 2017 Feb;92(2):161–170.
Journal cover image

Published In

American Journal of Hematology

DOI

EISSN

1096-8652

ISSN

0361-8609

Publication Date

February 2017

Volume

92

Issue

2

Start / End Page

161 / 170

Publisher

Wiley

Related Subject Headings

  • Immunology
  • 1102 Cardiorespiratory Medicine and Haematology